Argent BioPharma Limited (LON:MXC – Get Free Report) shares rose 4.8% on Friday . The stock traded as high as GBX 22 ($0.28) and last traded at GBX 22 ($0.28). Approximately 264 shares were traded during trading, a decline of 99% from the average daily volume of 26,353 shares. The stock had previously closed at GBX 21 ($0.27).
Argent BioPharma Stock Performance
The stock has a fifty day moving average of GBX 22 and a 200-day moving average of GBX 21.75. The firm has a market capitalization of £9.65 million, a price-to-earnings ratio of -13.25 and a beta of 1.03.
Argent BioPharma Company Profile
MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
See Also
- Five stocks we like better than Argent BioPharma
- When to Sell a Stock for Profit or Loss
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- Insider Trading – What You Need to Know
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Invest in the FAANG Stocks
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Argent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
